Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Genitourinary 2Dermatologic 1

Conditions

Carcinoma, Hepatocellular 129Carcinoma, Renal Cell 36Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 27Cholangiocarcinoma 23Endometrial Neoplasms 19Liver Neoplasms 16Melanoma 15Thyroid Neoplasms 13Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 12Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma 4Thyroid Cancer, Papillary 3Solid Tumors 3

Interventions

Temozolomide 162Radiosurgery 114Radiotherapy 99Bevacizumab 95Magnetic Resonance Spectroscopy 64Carboplatin 48Etoposide 34Surgical Procedures, Operative 33Irinotecan 33pembrolizumab 32Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 29Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × lenvatinib × Clear all
NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Recruiting
104 enrolled
CNS

Brain Neoplasms, Neoplasms

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡